TY - JOUR
T1 - Healthcare-associated pneumonia in acute care hospitals in European union/European economic area countries
T2 - An analysis of data from a point prevalence survey, 2011 to 2012
AU - ECDC PPS study group
AU - Walter, Jan
AU - Haller, Sebastian
AU - Quinten, Chantal
AU - Kärki, Tommi
AU - Zacher, Benedikt
AU - Eckmanns, Tim
AU - Abu Sin, Muna
AU - Plachouras, Diamantis
AU - Kinross, Pete
AU - Suetens, Carl
AU - Strauss, Reinhild
AU - Mertens, Karl
AU - Dobreva, Elina
AU - Budimir, Ana
AU - Hadjiloucas, Avgi
AU - Prattingerová, Jana
AU - Kristensen, Brian
AU - Monnet, Dominique L.
AU - Märtin, Pille
AU - Lyytikäinen, Outi
AU - Giard, Marine
AU - Piening, Brar
AU - Kritsotakis, Evangelos I.
AU - Kurcz, Andrea
AU - Gudlaugsson, Ólafur
AU - Burns, Karen
AU - Moro, Maria Luisa
AU - Dumpis, Uga
AU - Ašembergienė, Jolanta
AU - Heisbourg, Elisabeth
AU - Xuereb, Deborah
AU - Hopmans, Titia
AU - Sorknes, Nina Kristine
AU - Deptuła, Aleksander
AU - Paiva, Josá Artur
AU - Serban, Roxana
AU - Litvová, Slavka
AU - Kolman, Jana
AU - Lozano, Javier
AU - Struwe, Johan
AU - Hopkins, Susan
AU - Doherty, Lorraine
AU - Reilly, Jacqui S.
AU - Harrison, Wendy
N1 - Publisher Copyright:
© 2018, European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2018/8/9
Y1 - 2018/8/9
N2 - An aim of the ECDC point prevalence survey (PPS) in European Union/European Economic Area acute care hospitals was to acquire standardised healthcare-associated infections (HAI) data. We analysed one of the most common HAIs in the ECDC PPS, healthcare-associated pneumonia (HAP). Standardised HAI case definitions were provided and countries were advised to recruit nationally representative subsets of hospitals. We calculated 95% confidence intervals (CIs) around prevalence estimates and adjusted for clustering at hospital level. Of 231,459 patients in the survey, 2,902 (1.3%; 95% CI: 1.2–1.3) fulfilled the case definition for a HAP. HAPs were most frequent in intensive care units (8.1%; 95% CI: 7.4–8.9) and among patients intubated on the day of the survey (15%; 95% CI: 14–17; n = 737 with HAP). The most frequently reported microorganism was Pseudomonas aeruginosa (17% of 1,403 isolates), followed by Staphylococcus aureus (12%) and Klebsiella spp. (12%). Antimicrobial resistance was common among isolated microorganisms. The most frequently prescribed antimicrobial group was penicillins, including combinations with beta-lactamase inhibitors. HAPs occur regularly among intubated and non-intubated patients, with marked differences between medical specialities. HAPs remain a priority for preventive interventions, including surveillance. Our data provide a reference for future prevalence of HAPs at various settings.
AB - An aim of the ECDC point prevalence survey (PPS) in European Union/European Economic Area acute care hospitals was to acquire standardised healthcare-associated infections (HAI) data. We analysed one of the most common HAIs in the ECDC PPS, healthcare-associated pneumonia (HAP). Standardised HAI case definitions were provided and countries were advised to recruit nationally representative subsets of hospitals. We calculated 95% confidence intervals (CIs) around prevalence estimates and adjusted for clustering at hospital level. Of 231,459 patients in the survey, 2,902 (1.3%; 95% CI: 1.2–1.3) fulfilled the case definition for a HAP. HAPs were most frequent in intensive care units (8.1%; 95% CI: 7.4–8.9) and among patients intubated on the day of the survey (15%; 95% CI: 14–17; n = 737 with HAP). The most frequently reported microorganism was Pseudomonas aeruginosa (17% of 1,403 isolates), followed by Staphylococcus aureus (12%) and Klebsiella spp. (12%). Antimicrobial resistance was common among isolated microorganisms. The most frequently prescribed antimicrobial group was penicillins, including combinations with beta-lactamase inhibitors. HAPs occur regularly among intubated and non-intubated patients, with marked differences between medical specialities. HAPs remain a priority for preventive interventions, including surveillance. Our data provide a reference for future prevalence of HAPs at various settings.
UR - http://www.scopus.com/inward/record.url?scp=85052538776&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2018.23.32.1700843
DO - 10.2807/1560-7917.ES.2018.23.32.1700843
M3 - Article
C2 - 30107871
AN - SCOPUS:85052538776
VL - 23
JO - Eurosurveillance
JF - Eurosurveillance
SN - 1025-496X
IS - 32
M1 - 1700843
ER -